Pembrolizumab With Talimogene Laherparepvec or Placebo in Unresected Melanoma
Public ClinicalTrials.gov record NCT02263508. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1b/3, Multicenter, Trial of Talimogene Laherparepvec in Combination With Pembrolizumab (MK-3475) for Treatment of Unresectable Stage IIIB to IVM1c Melanoma (MASTERKEY-265)
Study identification
- NCT ID
- NCT02263508
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Amgen
- Industry
- Enrollment
- 713 participants
Conditions and interventions
Conditions
Interventions
- Pembrolizumab Drug
- Placebo Drug
- Talimogene Laherparepvec Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 95 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 7, 2014
- Primary completion
- Mar 10, 2021
- Completion
- Mar 10, 2021
- Last update posted
- Nov 13, 2022
2014 – 2021
United States locations
- U.S. sites
- 41
- U.S. states
- 19
- U.S. cities
- 35
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Birmingham | Alabama | 35243 | — |
| Research Site | Mobile | Alabama | 36608 | — |
| Research Site | Beverly Hills | California | 90211 | — |
| Research Site | Duarte | California | 91010 | — |
| Research Site | Encinitas | California | 92024 | — |
| Research Site | La Jolla | California | 92037 | — |
| Research Site | Los Angeles | California | 90024 | — |
| Research Site | Los Angeles | California | 90025 | — |
| Research Site | Riverside | California | 92505 | — |
| Research Site | San Francisco | California | 94115 | — |
| Research Site | San Francisco | California | 94117 | — |
| Research Site | Santa Monica | California | 90404 | — |
| Research Site | Miami | Florida | 33136 | — |
| Research Site | Miami Beach | Florida | 33140 | — |
| Research Site | Orlando | Florida | 32806 | — |
| Research Site | Atlanta | Georgia | 30322 | — |
| Research Site | Chicago | Illinois | 60611 | — |
| Research Site | Chicago | Illinois | 60637 | — |
| Research Site | Louisville | Kentucky | 40202 | — |
| Research Site | Baltimore | Maryland | 21237 | — |
| Research Site | Boston | Massachusetts | 02215 | — |
| Research Site | Detroit | Michigan | 48201 | — |
| Research Site | Fridley | Minnesota | 55432 | — |
| Research Site | St Louis | Missouri | 63110-1093 | — |
| Research Site | Hackensack | New Jersey | 07601 | — |
| Research Site | Buffalo | New York | 14263 | — |
| Research Site | New York | New York | 10016 | — |
| Research Site | New York | New York | 10032 | — |
| Research Site | New York | New York | 10065 | — |
| Research Site | Cincinnati | Ohio | 45209 | — |
| Research Site | Cleveland | Ohio | 44195 | — |
| Research Site | Philadelphia | Pennsylvania | 19107 | — |
| Research Site | Philadelphia | Pennsylvania | 19111 | — |
| Research Site | Pittsburgh | Pennsylvania | 15232 | — |
| Research Site | Germantown | Tennessee | 38138 | — |
| Research Site | Knoxville | Tennessee | 37920 | — |
| Research Site | Nashville | Tennessee | 37232 | — |
| Research Site | Dallas | Texas | 75246 | — |
| Research Site | Murray | Utah | 84107 | — |
| Research Site | Salt Lake City | Utah | 84112 | — |
| Research Site | Seattle | Washington | 98109-1023 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 120 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02263508, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 13, 2022 · Synced May 7, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02263508 live on ClinicalTrials.gov.